Reviews
1 April 1993

Drug-Induced Disorders of Glucose Tolerance

Publication: Annals of Internal Medicine
Volume 118, Number 7

Abstract

Purpose:

To review the medications that influence glucose metabolism and to examine the mechanisms of these medications on glucose metabolism.

Data Sources:

Data were obtained from a MEDLINE search back to 1966 and included animal and human studies published in the English language.

Study Selection:

Approximately 80% of original publications were included after review by the authors. Case reports were included if they provided additional information.

Date Extraction:

The original data from the literature were included on the basis of independent extraction by the authors.

Data Synthesis:

Many common therapeutic agents influence glucose metabolism. Multiple mechanisms of action on glucose metabolism exist through pancreatic, hepatic, and peripheral effects. Based on circumstances at the time of use, a drug may cause both hyper- and hypoglycemia in a patient. The patient's previous pancreatic reserve, nutritional state, use of other medication, or exposure to alcohol may influence the direction of the plasma glucose alterations.

Conclusion:

Hyperinsulinemia and insulin resistance form an intrinsic component of diabetes, hyperlipidemia, and atherosclerotic vascular disease (syndrome X). The induction of hyperinsulinemia and insulin resistance by medication may therefore counteract intended benefits. An extensive review of recent medication in patients with disorders of glucose tolerance and the avoidance of polypharmacy are recommended. It is prudent to monitor plasma glucose values when it is not possible to avoid prescription of medication with known effects on carbohydrate metabolism.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Caranasos GJ, Stewart RB, Cluff LE. Drug-induced illness leading to hospitalization. JAMA. 1974; 228:713-7.
2.
Lakshmanan MC, Hershey CO, Breslau D. Hospital admissions caused by iatrogenic disease. Arch Intern Med. 1986; 146:1931-4.
3.
Karch FE, Lasagna L. Adverse drug reactions. A critical review. JAMA. 1975; 234:1236-41.
4.
Miller RR. Drug surveillance utilizing epidemiologic methods. A report from the Boston Collaborative Drug Surveillance Program. Am J Hosp Pharm. 1973; 30:584-92.
5.
Melmon KL. Preventable drug reactions—causes and cures. N Engl J Med. 1971; 284:1361-8.
6.
Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet. 1980; 1:1373-6.
7.
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37:1595-607.
8.
Peiris AN, Sothmann MS, Hoffmann RG, Hennes MI, Wilson CR, Gustafson AB, et al. Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med. 1989; 110:867-72.
9.
Ames RP. Negative effects of diuretic drugs on metabolic risk factors for coronary heart disease: possible alternative drug therapies. Am J Cardiol. 1983; 51:632-8.
10.
Breckenridge A, Welborn TA, Dollery CT, Fraser R. Glucose tolerance in hypertensive patients on long-term diuretic therapy. Lancet. 1967; 1:61-4.
11.
Lewis PJ, Kohner EM, Petrie A, Dollery CT. Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment. Lancet. 1976; 1:564-6.
12.
Cornish AL, McClellan JT, Johnston DH. Effects of chlorothiazide on the pancreas. N Engl J Med. 1961; 265:673-5.
13.
Helderman JH, Elahi D, Andersen DK, Raizes GS, Tobin JD, Schocken D, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes. 1983; 32: 106-11.
14.
Tourniaire J, Bajard L, Harfouch M, Rebattu B, Garrel D. (Restoration of insulin sensitivity after correction of hypokalemia due to chronic tubulopathy in a diabetic patient). Diabete Metab. 1988; 14:717-20.
15.
Flamenbaum W. Metabolic consequences of antihypertensive therapy. Ann Intern Med. 1983; 98:875-80.
16.
Davies DM. Textbook of Adverse Drug Reactions. New York: Oxford University Press; 1985:352-69.
17.
Beardwood DM, Alden JS, Graham CA, Beardwood JT, Marble A. Evidence for a peripheral action of hydrochlorothiazide in normal man. Metabolism. 1965; 14:561-7.
18.
Hermansen K, Schmitz O, Mogensen CE. Effects of a thiazide diuretic (hydroflumethiazide) and a loop diuretic (bumetanide) on the endocrine pancreas: studies in vitro. Metabolism. 1985; 34: 784-9.
19.
Kaplan NM. Non-drug treatment of hypertension. Ann Intern Med. 1985; 102:359-73.
20.
Campbell DB, Moore RA. The pharmacology and clinical pharmacology of indapamide. Postgrad Med J. 1981; 57(Suppl 2):7-17.
21.
Osei K, Holland G, Falko JM. Indapamide. Effects on apoprotein, lipoprotein, and glucoregulation in ambulatory diabetic patients. Arch Intern Med. 1986; 146:1973-7.
22.
Cowley AJ, Elkeles RS. Diabetes and therapy with potent diuretics (Letter). Lancet. 1978; 1:154.
23.
Guigliano D, Torella R, Sgambato S, D'Onofrio F. Acetylsalicylic acid restores acute insulin response reduced by fursemide in man. Diabetes. 1979; 28:841-5.
24.
Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987; 60:820-5.
25.
Metz SA, Halter JB, Robertson RP. Induction of defective insulin secretion and impaired glucose tolerance by clonidine. Selective stimulation of metabolic α-adrenergic pathways. Diabetes. 1978; 27:554-62.
26.
Sung PK, Samet P, Yeh BK. Effects of clonidin and chlorthalidone on blood pressure and glucose tolerance in hypertensive patients. Curr Ther Res Clin Exp. 1971; 13:280-5.
27.
Cerasi E, Luft R, Efendic S. Effect of adrenergic blocking agents on insulin response to glucose infusion in man. Acta Endocrinol (Copenh). 1972; 69:335-46.
28.
Micossi P, Pollavini G, Raggi U, Librenti MC, Garimberti B, Beggi P. Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus. Horm Metab Res. 1984; 16: 59-63.
29.
Whitcroft I, Wilkinson N, Rawthorne A, Thomas J, Davies JB. Beta-adrenoreceptor antagonist impair long-term glucose control in hypertensive diabetics: role of β-adrenoreceptor selectivity and lipid solubility. Br J Clin Pharm. 1986; 22:236-7P.
30.
Whitcroft I. Do antihypertensive drugs precipitate diabetes? (Letter). Br Med J (Clin Res Ed). 1985; 290:322.
31.
Totterman K, Groop L, Groop PH, Kala R, Tolppanen EM. Effect of β-blocking drugs on β-cell function and insulin sensitivity in hypertensive non-diabetic patients. Eur J Clin Pharmacol. 1984; 26:13-7.
32.
Wollheim CB, Kikuchi M, Renold AE, Sharp CW. The roles of intracellular and extracellular Ca++ in glucose-stimulated biphasic insulin release by rat islets. J Clin Invest. 1978; 62:451-8.
33.
Bhatnagar SK, Amin MM, Al-Yusuf AR. Diabetogenic effects of nifedipine. Br Med J (Clin Res Ed). 1984; 289:19.
34.
Heyman SN, Heyman A, Halperin I. Diabetogenic effect of nifedipine. DICP. 1989; 23:236-7.
35.
Lund-Johansen P. Clinical use of calcium antagonists in hypertension: update 1986. J Cardiovasc Pharmacol. 1987; 10(Suppl):S29-35.
36.
Dante A. Nifedipine and fasting glycemia (Letter). Ann Intern Med. 1986; 104:125-6.
37.
Andersson DE, Rojdmark S. Improvement of glucose tolerance by verapamil in patients with non–insulin-dependent diabetes mellitus. Acta Med Scand. 1981; 210:27-33.
38.
Roth A, Miller HI, Belhassen B, Laniado S. Slow-release verapamil and hyperglycemic metabolic acidosis (Letter). Ann Intern Med. 1989; 110:171-2.
39.
Jones BJ, McKenney JM, Wright JT Jr, Goodman RP. Effects of diltiazem hydrochloride on glucose tolerance in persons at risk for diabetes mellitus. Clin Pharm. 1988; 7:235-8.
40.
Pershadsingh HA, Grant N, McDonald JM. Association of diltiazem therapy with increased insulin resistance in a patient with type I diabetes mellitus (Letter). JAMA. 1987; 257:930-1.
41.
Lederballe Pedersen O. Long-term experiences with minoxidil in combination treatment of severe arterial hypertension. Acta Cardiol. 1977; 32:283-93.
42.
Brass EP. Effects of antihypertensive drugs on endocrine function. Drugs. 1984; 27:447-58.
43.
Chan JC, Cockram CS. Drug-induced disturbances of carbohydrate metabolism. Adverse Drug React Toxicol Rev. 1991; 10:1-29.
44.
Long CN, Katzin B, Fry EG. The adrenal cortex and carbohydrate metabolism. Endocrinology. 1940; 26:309-44.
45.
Olefsky JM, Kimmerling G. Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci. 1976; 271:201-10.
46.
Pagano G, Cavalco-Perin P, Cassader M, Bruno A, Ozzello A. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest. 1983; 72:1814-20.
47.
Yasuda K, Kitabchi AE. Decreased insulin binding of human erythrocytes after dexamethazone or prednisone ingestion. Diabetes. 1980; 29:811-4.
48.
Yasuda K, Hines E, Kitabchi AE. Hypercorticolism and insulin resistance: Comparative effects of Prednisone, Hydrocortisone, and Dexamethazone on insulin binding of human erythrocytes. J Clin Endocrinol Metab. 1982; 55:910-5.
49.
Corcoran FH, Granatir RF, Schlang HA. Hyperglycemic hyperosmolar nonketotic coma associated with corticosteroid therapy. J Fla Med Assoc. 1971; 58:38-9.
50.
Cornell RC, Stoughton RB. The use of topical steroids in psoriasis. Dermatologic Clin. 1984; 2:397-409.
51.
Hallam NF. The use and abuse of topical corticosteroids in dermatology. Scott Med J. 1980; 25:287-91.
52.
Greenstone MA, Shaw AB. Alternate day corticosteroid causes alternate day hyperglycaemia. Postgrad Med J. 1987; 63:761-4.
53.
Bending JJ, Ogg CS, Viberti GC. Diabetogenic effect of cyclosporin. Br Med J (Clin Res Ed). 1987; 294:401-2.
54.
Ferrero E, Marni A, Ferrero ME, Gaja G, Rugarli C. Effect of cyclosporine and aminophylline on streptozotocin-induced diabetes in rats. Immunol Lett. 1985; 10:183-7.
55.
Iwakiri R, Nagafuchi S, Kounoue E, Nakano S, Koga T, Nakayama M, et al. Cyclosporin A enhances streptozocin-induced diabetes in CD-1 mice. Experientia. 1987; 43:324-7.
56.
Sestier C, Odent-Pogu S, Bonneville M, Maurel C, Lang F, Sai P. Cyclosporin enhances diabetes induced by low-dose streptozotocin treatment in mice. Immunol Lett. 1985; 10:57-60.
57.
Ost L, Tyden G, Fehrman I. Impaired glucose tolerance in cyclosporine-prednisolone-treated renal graft recipients. Transplantation. 1988; 46:370-2.
58.
Yoshimura N, Nakai I, Ohmori Y, Aikawa I, Fukuda M, Yasumura T, et al. Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients. Am J Kidney Dis. 1988; 12:11-7.
59.
Pollock SH, Reichbaum MI, Collier BH, D'Souza MJ. Inhibitory effect of cyclosporine A on the activity of oral hypoglycemic agents in rats. J Pharmacol Exp Ther. 1991; 258:8-12.
60.
Said DM, Fraga JR, Reichelderfer TE. Hyperglycemia associated with diphenylhydantoin (Dilantin) intoxication. Med Ann Dist Columbia. 1968; 37:170-2.
61.
Callaghan N, Feely M, O'Callaghan M, Duggan B, McGarry J, Cramer B, et al. The effects of toxic and non-toxic serum phenytoin levels on carbohydrate tolerance and insulin levels. Acta Neurol Scand. 1977; 56:563-71.
62.
Levin SR, Reed JW, Ching KN, Davis JW, Blum MR, Forsham PH. Diphenylhydantoin. Its use in detecting early insulin secretory defects in patients with mild glucose intolerance. Diabetes. 1973; 22:194-201.
63.
Fariss BL, Lutcher CL. Diphenylhydantoin-induced hyperglycemia and impaired insulin release. Effect of dosage. Diabetes. 1971; 20: 177-81.
64.
Peters BH, Samaan NA. Hyperglycemia with relative hypoinsulinemia in diphenylhydantoin toxicity. N Engl J Med. 1969; 281:91-2.
65.
Flohr K, Kiesel U, Freytag G, Kolb H. Insulitis as a consequence of immune dysregulation: further evidence. Clin Exp Immunol. 1983; 53:605-13.
66.
Perry-Keene DA, Larkins RG, Heyma P, Peter CT, Ross D, Sloman JG. The effect of long-term diphenylhydantoin therapy on glucose tolerance and insulin secretion: a controlled trial. Clin Endocrinol (Oxf). 1980; 12:575-80.
67.
Minaker KL, Flier JS, Landsberg L, Young JB, Moxley RT, Kingston WJ, et al. Phenytoin-induced improvement in muscle cramping and insulin action in three patients with the syndrome of insulin resistance, acanthosis nigricans, and acral hypertrophy. Arch Neurol. 1989; 46:981-5.
68.
Fioretti P, Genazzani AR, Felber JP, Facchini V, Onano AM, Romagnino S, et al. Glucose and insulin tolerance throughout the menstrual cycle. Acta Eur Fertil. 1975; 6:63-71.
69.
Valdes CT, Elkind-Hirsch KE. Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab. 1991; 72:642-6.
70.
Ryan EA, O'Sullivan MJ, Skyler JS. Insulin action during pregnancy. Studies with the euglycemic clamp technique. Diabetes. 1985; 34:380-9.
71.
Carrington LJ, Bailey CJ. Influence of administration route and treatment duration on the glucoregulatory effects of sex steroids in female mice. Gen Pharmacol. 1984; 15:415-7.
72.
Ballejo G, Saleem TH, Khan-Dawood FS, Tsibris JC, Spellacy WN. The effect of sex steroids on insulin binding by target tissues in the rat. Contraception. 1983; 28.
73.
De Pirro R, Forte F, Bertoli A, Greco AV, Lavro R. Changes in insulin receptors during oral contraception. J Clin Endocrinol Metab. 1981; 52:29-33.
74.
Friedl KE, Jones RE, Hannan CJ Jr, Plymate SR. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. J Clin Endocrinol Metab. 1989; 68: 971-5.
75.
Buffington CK, Givens JR, Kitabchi AE. Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. Diabetes. 1991; 40:693-700.
76.
Wynn V, Doar JW. Some effects of oral contraceptives on carbohydrate metabolism. Lancet. 1969; 2:761-5.
77.
Kasdorf G, Kalkhoff RK. Prospective studies of insulin sensitivity in normal women receiving oral contraceptive agents. J Clin Endocrinol Metab. 1988; 66:846-52.
78.
Wynn V, Adams PW, Godsland I, Melrose J, Niththyananthan R, Oakley NW, et al. Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet. 1979; 1:1045-9.
79.
Javier Z, Gershberg H, Hulse M. Ovulatory suppressants, estrogens and carbohydrate metabolism. Metabolism. 1968; 17:443-56.
80.
Goldzieher JW, Chenault CB, De La Pena A, Dozier TS, Kraemer DC. Comparative studies of the ethynyl estrogens used in oral contraceptives. VI. Effects with and without progestational agents on carbohydrate metabolism in humans, baboons, and beagles. Fertil Steril. 1978; 30:146-53.
81.
Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB. Effects of low doses of transdermal 17 β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab. 1992; 74:1396-400.
82.
Perlman JA, Russell-Briefel R, Ezzati T, Lieberknecht G. Oral glucose tolerance and the potency of contraceptive progestins. J Chronic Dis. 1985; 38:857-64.
83.
Spellacy WN, Buhi WC, Birk SA. Carbohydrate and lipid studies in women using the progesterone intrauterine device for one year. Fertil Steril. 1979; 31:381-4.
84.
Spellacy WN. The effects of oral contraceptives on carbohydrate metabolism. J Reprod Med. 1970; 5:20-4.
85.
Spellacy WN, Tsibris JC, Ellingson AB. Carbohydrate metabolic studies in women using a levonorgestrel/ethinyl estradiol containing triphasic oral contraceptive for eighteen months. Int J Gynaecol Obstet. 1991; 35:69-71.
86.
Spellacy WN. Carbohydrate metabolism during treatment with estrogen, progestogen and low-dose oral contraceptives. Am J Obstet Gynecol. 1982; 142:732-4.
87.
Skouby SO, Jensen BM, Kuhl C, Molsted-Pederson L, Svenstrup B, Nielsen J. Hormonal contraception in diabetic women: acceptability and influence on diabetes control and ovarian function of a nonalkylated estrogen/progestogen compound. Contraception. 1985; 32:23-31.
88.
Tornvall P, Walldius G. A comparison between nicotinic acid and acipimox in hypertriglyceridaemia—effects on serum lipids, lipoproteins, glucose tolerance and tolerability. J Intern Med. 1991; 230:415-21.
89.
Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, et al. Increased β-cell secretory capacity as a mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 1989; 38:562-8.
90.
McCulloch DK, Kahn SE, Schwartz MW, Koerker DJ, Palmer JP. Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons. J Clin Invest. 1991; 87:1395-401.
91.
Henkin Y, Oberman A, Hurst DC, Segrest JP. Niacin revisited: clinical observations on an important but underutilized drug. Am J Med. 1991; 91:239-46.
92.
Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med. 1988; 148:2493-5.
93.
Hale PJ, Nattrass M. The short-term effect of nicotinic acid on intermediary metabolism in insulin-dependent diabetes mellitus. Ann Clin Biochem. 1991; 28:39-43.
94.
Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non–insulin-dependent diabetes mellitus. JAMA. 1990; 264:723-6.
95.
Fulcher GR, Jones IR, Alberti KG. Improvement in glucose tolerance by reduction of lipid concentrations in non-insulin dependent diabetes mellitus. Diabetes News. 1988; 9:4-8.
96.
Regal H, Lageder H, Irsigler K, Maggi E, Mandelli V. Effect of a single oral dose of acipox on glucose utilization after intravenous glucose load in obese patients. Drugs Exp Clin Res. 1984; 10:621-5.
97.
Muggeo M. Acipimox Co-operative Italian Group, University of Verona. Long term multicentre trial with acipimox in diabetic patients with hyperlipoproteinemia. Proceedings of the 6th international meeting on Atherosclerosis and Cardiovascular diseases. Bologna; 1986.
98.
Arneson GA. Phenothiazine derivatives and glucose metabolism. J Neuropsychiatr. 1964; 5:181-98.
99.
Korenyi C, Lowenstein B. Chlorpromazine induced diabetes. Dis Nerv Syst. 1968; 29:827-8.
100.
Krausz Y, Eylon L, Cerasi E. Calcium-binding proteins and insulin release. Differential effects of phenothiazines on first- and second-phase secretion and on islet cAMP response to glucose. Acta Endocrinol (Copenh). 1987; 116:241-6.
101.
Zofkova I, Stolba P. Effect of calcitriol and trifluoperazine on glucose stimulated B cell function in healthy humans. Exp Clin Endocrinol. 1990; 96:185-91.
102.
Sato S, Katayama K, Kakemi M, Koizumi T. A kinetic study of chlorpromazine on the hyperglycemic response in rats. II. Effect of chlorpromazine on plasma glucose. J Pharmacobiodyn. 1988; 11: 492-503.
103.
Erle G, Basso M, Federspil G, Sicolo N, Scandellari C. Effect of chlorpromazine on blood glucose and plasma insulin in man. Eur J Clin Pharmacol. 1977; 11:15-8.
104.
Lazarus JH. Endocrine and Metabolic Effects of Lithium. New York: Plenum Medical Book Co.; 1986.
105.
Agbayewa MO. Glycosylated hemoglobin (risk of diabetes mellitus) in lithium therapy. Psychiatr J Univ Ott. 1986; 11:153-5.
106.
Russell JD, Johnson GF. Affective disorders, diabetes mellitus and lithium. Aust N Z J Psychiatry. 1981; 15:349-53.
107.
Muller-Oerlinghausen B, Passoth PM, Poser W, Pudel V. Impaired glucose tolerance in long-term lithium-treated patients. Int Pharmacopsychiatry. 1979; 14:350-62.
108.
van der Velde CD, Gordon MW. Manic-depressive illness, diabetes mellitus, and lithium carbonate. Arch Gen Psychiatry. 1969; 21:478-85.
109.
Vestergaard P, Schou M. Does long-term lithium treatment induce diabetes mellitus? Neuropsychobiology. 1987; 17:130-2.
110.
Saito T, Sato T, Yamamoto M, Kokubun M, Ito M, Inoue M, et al. Hemoglobin Ai levels in hyperthyroidism. Endocrinol Jpn. 1982; 29:137-40.
111.
Yasuda K, Saito S, Yamamoto M, Okuyama M, Yoshinaga K, Miura K. Carbohydrate metabolism in subacute thyroiditis: effect of acute elevation of thyroid hormones. Tohoku J Exp Med. 1981; 134:411-6.
112.
Bratusch-Marrain PR, Gasic S, Waldhausl WK. Triiodothyronine increases splanchnic release and peripheral uptake of glucose in healthy humans. Am J Physiol. 1984; 247:E681-7.
113.
Lenzen S, Bailey CJ. Thyroid hormones, gonadal and adrenocortical steroids and the function of the islets of Langerhans. Endocr Rev. 1984; 5:411-34.
114.
Cavallo-Perin P, Bruno A, Bozzo C, Boine L, Estivi P, Martina V, et al. Insulin binding to monocytes and in vivo peripheral insulin sensitivity are normal in Graves' disease. J Endocrinol Invest. 1988; 11:795-800.
115.
Karlander SG, Khan A, Wajngot A, Torring O, Vranic M, Efendic S. Glucose turnover in hyperthyroid patients with normal glucose tolerance. J Clin Endocrinol Metab. 1989; 68:780-6.
116.
Taylor R, McCulloch AJ, Zeuzem S, Gray P, Clark F, Alberti KG. Insulin secretion, adipocyte insulin binding and insulin sensitivity in thyrotoxicosis. Acta Endocrinol (Copenh). 1985; 109:96-103.
117.
O'Byrne S, Feely J. Effects of drugs on glucose tolerance in non–insulin-dependent diabetics (Part II). Drugs. 1990; 40:6-18.
118.
Leslie D, Coats PM. Salbutamol-induced diabetic ketoacidosis (Letter). Br Med J. 1977; 2:768.
119.
Main EK, Main DM, Gabbe SG. Chronic oral terbutaline tocolytic therapy is associated with maternal glucose intolerance. Am J Obstet Gynecol. 1987; 157:644-7.
120.
Main DM, Main EK, Strong SE, Gabbe SG. The effect of oral ritodrine therapy on glucose tolerance in pregnancy. Am J Obstet Gynecol. 1985; 152:1031-3.
121.
Rosati G, Maioli M, Aiello I, Farris A, Agnetti V. Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson's disease. Eur Neurol. 1976; 14:229-39.
122.
Ellis ME, Weiss RB, Korzun AH, Rice MA, Norton L, Perloff M, et al. Hyperglycemic complications associated with adjuvant chemotherapy of breast cancer. A cancer and leukemia group B (CALGB) study. Am J Clin Oncol. 1986; 9:533-6.
123.
Salerno DM, Fifield J, Krejci J, Hodges M. Encainide-induced hyperglycemia. Am J Med. 1988; 84:39-44.
124.
Hall KW, Dobson KE, Dalton JG, Ghignone MC, Penner SB. Metabolic abnormalities associated with intentional theophylline overdose. Ann Intern Med. 1984; 101:457-62.
125.
Dickson I. Glycosuria and diabetes following INAH therapy. Med J Aust. 1962; 1:325-6.
126.
Kurz M. (Diamox and manifestation of diabetes mellitus.) Wien Med Wochenschr. 1968; 118:239.
127.
Asensio AS, Caticha-Alfonso OS, Beiguelman B, Magna LA. Diabetogenic effect of dapsone (Letter). Int J Lepr Other Mycobact Dis. 1987; 55:357-8.
128.
Fraser AG, Harrower AD. Convulsions and hyperglycaemia associated with nalidixic acid. Br Med J. 1977; 2:1518.
129.
Takasu N, Yamada T, Miura H, Sakamoto S, Korenaga M, Nakajima K, et al. Rifampicin-induced early phase hyperglycemia in humans. Am Rev Respir Dis. 1982; 125:23-7.
130.
Tkach JR. Indomethacin-induced hyperglycemia in psoriatic arthritis (Letter). J Am Acad Dermatol. 1982; 7:802-3.
131.
Zumoff B, Hellman L. Aggravation of diabetic hyperglycemia by chlordiazepoxide. JAMA. 1977; 237:1960-1.
132.
Hayakawa F, Hakamada S, Kuno K, Nakashima T, Miyachi Y. Doxapram in the treatment of idiopathic apnea of prematurity: desirable dosage and serum concentrations. J Pediatr. 1986; 109: 138-40.
133.
Tollefson G, Lesar T. Nonketotic hyperglycemia associated with loxapine and amoxapine: case report. J Clin Psychiatry. 1983; 44: 347-8.
134.
Politi A, Poggio G, Margiotta A. Can amiodarone induce hyperglycaemia and hypertriglyceridaemia? Br Med J (Clin Res Ed.). 1984; 288:285.
135.
Seltzer HS. Drug-induced hypoglycemia. A review of 1418 cases. Endocrinol Metab Clin North Am. 1989; 18:163-83.
136.
Mortimer EA, Lepow ML. Varicella with hypoglycemia possibly due to salicylates. Am J Dis Child. 1962; 103:91-8.
137.
Cotton EK, Fahlberg YI. Hypoglycemia with salicylate poisoning. Am J Dis Child. 1964; 108:171-3.
138.
Gilgore SG. The influence of salicylate on hyperglycemia. Diabetes. 1960; 9:392-3.
139.
Hecht A, Goldner MG. Reappraisal of the hypoglycemic action of acetylsalicylate. Metabolism. 1959; 8:418-28.
140.
Newman WP, Brodows RG. Aspirin causes tissue insensitivity to insulin in normal man. J Clin Endocrinol Metab. 1983; 57:1102-6.
141.
Arky RA. Hypoglycemia associated with liver disease and ethanol. Endocrinol Metab Clin North Am. 1989; 18:75-90.
142.
Bratusch-Marrain PR, Vierhapper H, Komjati M, Waldhausl WK. Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non–insulin-dependent diabetic men. Diabetologia. 1985; 28:671-6.
143.
Giugliano D, Ceriello A, Saccomanno F, Quatraro A, Paolisso G, D'Onofrio F. Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1985; 61:160-6.
144.
Frankel MC, Leslie BR, Sax FL, Soave R. Trimethoprim-sulfamethoxazole-related hypoglycemia in a patient with renal failure. N Y State J Med. 1984; 84:30-1.
145.
Arem R, Garber AJ, Field JB. Sulfonamide-induced hypoglycemia in chronic renal failure. Arch Intern Med. 1983; 143:827-9.
146.
Poretsky L, Moses AC. Hypoglycemia associated with trimethoprim/sulphamethoxazole therapy (Letter). Diabetes Care. 1984; 7:508-9.
147.
Kotler MN, Berman L, Rubenstein AH. Hypoglycaemia precipitated by propanolol. Lancet. 1966; 2:1389-90.
148.
Barnett AH, Leslie D, Watkins PJ. Can insulin-treated diabetics be given β-adrenergic blocking drugs? Br Med J. 1980; 280:976-8.
149.
Grajower MM, Walter L, Albin J. Hypoglycemia in chronic hemodialysis patients: association with propanolol use. Nephron. 1980; 26:126-9.
150.
Cottrill CM, McAllister RG Jr, Gettes L, Noonan JA. Propanolol therapy during pregnancy, labor, and delivery: evidence for transplacental drug transfer and impaired neonatal drug disposition. J Pediatr. 1977; 91:812-4.
151.
Angelo-Nielson K. Timolol topically and diabetes mellitus (Letter). JAMA. 1980; 244:2263.
152.
White NJ, Warrell DA, Chanthavanich P, Looareesuwan S, Warrell MJ, Krishna S, et al. Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med. 1983; 309:61-6.
153.
Phillips RE, Warrell DA, Looareesuwan S, Turner RC, Bloom SR, Quantrill D, et al. Effectiveness of SMS 201-995, a synthetic, long-acting somatostatin analogue, in treatment of quinine-induced hyperinsulinaemia. Lancet. 1986; 1:713-6.
154.
Smith GD, Amos TA, Mahler R, Peters TJ. Effect of chloroquine on insulin and glucose homeostasis in normal subjects and patients with non–insulin-dependent diabetes mellitus. Br Med J (Clin Res Ed). 1987; 294:465-7.
155.
Blazar BR, Whitley CB, Kitabchi AE, Tsai MY, Santiago J, White N, et al. In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance. Diabetes. 1984; 33:1133-7.
156.
Sai P, Boillot D, Boitard C, Debray-Sachs M, Reach G, Assan R. Pentamidine, a new diabetogenic drug in laboratory rodents. Diabetologia. 1983; 25:418-23.
157.
Shen M, Orwoll ES, Conte JE Jr, Prince MJ. Pentamidine-induced pancreatic β-cell dysfunction. Am J Med. 1989; 86:726-8.
158.
Jha TK, Sharma VK. Pentamidine-induced diabetes mellitus. Trans R Soc Trop Med Hyg. 1984; 78:252-3.
159.
Collins J, Pien FD, Houk JH. Insulin-dependent diabetes mellitus associated with pentamidine. Am J Med Sci. 1989; 297:174-5.
160.
Stahl-Bayliss CM, Kalman CM, Laskin OL. Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome. Clin Pharmacol Ther. 1986; 39:271-5.
161.
Ganda OP. Pentamidine and hypoglycemia (Letter). Ann Intern Med. 1984; 100:464.
162.
Bouchard P, Sai P, Reach G, Caubarrere I, Ganeval D, Assan R. Diabetes mellitus following pentamidine-induced hypoglycemia in humans. Diabetes. 1982; 31:40-5.
163.
Fitzgerald DB, Young IS. Reversal of pentamidine-induced hypoglycaemia with oral diazoxide. J Trop Med Hyg. 1984; 87:15-9.
164.
Waskin H, Stehr-Green JK, Helmick CG, Sattler FR. Risk factors for hypoglycemia associated with pentamidine therapy for pneumocystis pneumonia. JAMA. 1988; 260:345-7.
165.
Zuger A, Wolf BZ, el-Sadr W, Simberkoff MS, Rahal JJ. Pentamidine-associated fatal acute pancreatitis. JAMA. 1986; 256:2383-5.
166.
Salmeron S, Petitpretz P, Katlama C, Herve P, Brivet F, Simonneau G, et al. Pentamidine and pancreatitis (Letter). Ann Intern Med. 1986; 105:140-1.
167.
Klein RA, Calamin V. Prolonged hypoglycemia during pentamidine therapy. Clin Pharm. 1983; 2:505-6.
168.
Belehu A, Naafs B. Diabetes mellitus associated with pentamidine mesylate (Letter). Lancet. 1982; 1:1463-4.
169.
Epstein MF, Nicholls E, Stubblefield PG. Neonatal hypoglycemia after β-sympathomimetic tocolytic therapy. J Pediatr. 1979; 94: 449-53.
170.
Epstein MF, Nicholls E, Stubblefield PG. Neonatal hypoglycemia after β-sympathomimetic tocolytic therapy. J Pediatr. 1979; 94: 449-53.
171.
Brazy JE, Pupkin MJ. Effects of maternal isoxsuprine administration on preterm infants. J Pediatr. 1979; 94:444-8.
172.
Caldwell G, Scougall I, Boddy K, Toft AD. Fasting hyperinsulinemic hypoglycemia after ritodrine therapy for premature labor. Obstet Gynecol. 1987; 70:478-80.
173.
Nappi JM, Dhanani S, Lovejoy JR, VanderArk C. Severe hypoglycemia associated with disopyramide. West J Med. 1983; 138:95-7.
174.
Goldberg IJ, Brown LK, Rayfield EJ. Disopyramide (Norpace)-induced hypoglycemia. Am J Med. 1980; 69:463-6.
175.
Rubin M, Zakheim B, Pitchumoni C. Disopyramide-induced profound hypoglycemia. N Y State J Med. 1983; 83:1057-8.
176.
Quevedo SF, Krauss DS, Chazan JA, Crisafulli FS, Kahn CB. Fasting hypoglycemia secondary to disopyramide therapy. Report of two cases. JAMA. 1981; 245:2424.
177.
Croxson MS, Shaw DW, Henley PG, Gabriel HD. Disopyramide- induced hypoglycaemia and increased serum insulin. N Z Med J. 1987; 100:407-8.
178.
Stapleton JT, Gillman MW. Hypoglycemic coma due to disopyramide toxicity. South Med J. 1983; 76:1453.
179.
Madison LL. Ethanol-induced hypoglycemia. In: Levine R, Luft R; eds. Advances in Metabolic Disorders; vol. 3. New York: Academic Press, 1968:85-109.
180.
Peluffo E, Scolpini V, Grezzi J. Hypoglycemic coma from ingestion of alcohol drinks by children. Arch Pediatr Urug. 1958; 29:94-101.
181.
Cooper AJ, Ashcroft G. Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs. Lancet. 1966; 1:407-9.
182.
Van Praag HM, Leijnse B. Depression, glucose tolerance, peripheral glucose uptake and their alterations under the influence of anti-depressive drugs of the hydrazine type. Psychopharmacologia. 1965; 8:67-78.
183.
Adnitt PI. Hypoglycemic action of monoamineoxidase inhibitors (MAOI'S). Diabetes. 1968; 17:628-33.
184.
Kaplan JM, Mass JW, Pixley JM, Ross WD. Use of imipramine in diabetics. JAMA. 1960; 174:511-7.
185.
Mueller PS, Heninger GR, McDonald RK. Insulin tolerance test in depression. Arch Gen Psychiatry. 1969; 21:587-94.
186.
Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J. Captopril and insulin sensitivity (Letter). Ann Intern Med. 1985; 102:134-5.
187.
Jauch KW, Gunther B, Hartl W, Rett K, Wicklmayr M, Dietze G. Improvement of impaired postoperative insulin action by bradykinin. Biol Chem Hoppe Seyler. 1986; 367:207-10.
188.
McMurray J, Fraser DM. Captopril, enalapril, and blood glucose (Letter). Lancet. 1986; 1:1035.
189.
Lederle RM. Captopril and hydrochlorothiazide in the fixed combination multicenter trial. J Cardiovasc Pharmacol. 1985; 7(Suppl 1):S63-9.
190.
Elling P, Elling H. Penicillamine, captopril, and hypoglycemia (Letter). Ann Intern Med. 1985; 103:644-5.
191.
Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989; 321:868-73.
192.
Broadstone VL, Pfeifer MA, Bajaj V, Stagner JI, Samols E. Alpha-adrenergic blockade improves glucose-potentiated insulin secretion in non–insulin-dependent diabetes mellitus. Diabetes. 1987; 36: 932-7.
193.
Vester JW, Sunder JH, Aarons JH, Danowski TS. Long-term monitoring during clofibrate therapy. Clin Pharmacol Ther. 1970; 11: 689-97.
194.
Blane GF. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med. 1987; 83:26-36.
195.
Seviour PW, Teal TK, Richmond W, Elkeles RS. Serum lipids, lipoproteins and macrovascular disease in non–insulin-dependent diabetics: a possible new approach to treatment. Diabetic Med. 1988; 5:166-71.
196.
Fenderson RW, Deutsch S, Menachemi E, Chin B, Samuel P. Effect of gemfibrozil on serum lipids in man. Angiology. 1982; 33:581-93.
197.
Janda A, Salem C. (Hypoglycemia caused by lidocaine overdosage.) Reg Anaesth. 1986; 9:88-90.
198.
Hunt NJ. Hypoglycemic effect of lithium (Letter). Biol Psychiatry. 1987; 22:798-9.
199.
Shah JH, DeLeon-Jones FA, Schickler R, Nasr S, Mayer M, Hurks C. Symptomatic reactive hypoglycemia during glucose tolerance test in lithium-treated patients. Metabolism. 1986; 35:634-9.
200.
Hilleman DE, Mohiuddin SM, Ahmed IS, Dahl JM. Cibenzoline-induced hypoglycemia. Drug Intell Clin Pharm. 1987; 21:38-40.
201.
Phillips RE, Looareesuwan S, White NJ, Chanthavanich P, Karbwang J, Supanaranond W, et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. Br Med J (Clin Res Ed). 1986; 292:1319-21.
202.
Almirall J, Montoliu J, Torras A, Revert L. Propoxyphene-induced hypoglycemia in a patient with chronic renal failure. Nephron. 1989; 53:273-5.
203.
Garbitelli VP. Tetracycline reduces the need for insulin (Letter). N Y State J Med. 1987; 87:576.
204.
Caprio S, Ray TK, Boden G, Reichard GA Jr, Shuman CR, Smith RH, et al. Improvement of metabolic control in diabetic patients during mebendazole administration: preliminary studies. Diabetologia. 1984; 27:52-5.
205.
Small M, Forbes CD, MacCuish AC. Metabolic effects of stanozalol in type II diabetes mellitus. Horm Metab Res. 1986; 18:647-8.
206.
Peiris AN, Stagner JI, Plymate SR, Vogel RL, Heck M, Samols E. Relationship of insulin secretory pulses to sex hormone binding globulin levels in normal men. J Clin Endocrinol Metab. 1993; 76: 279-87.
207.
Peiris AN, Stagner JI, Vogel RL, Nakagawa A, Samols E. Body fat distribution and peripheral insulin sensitivity in normal men: role of insulin pulsatility. J Clin Endocrinol Metab. 1992; 75:290-4.
208.
Connor H, Marks V. Alcohol and diabetes. Diabet Med. 1985; 2: 413-6.

Information & Authors

Information

Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 118Number 71 April 1993
Pages: 529 - 539

History

Published in issue: 1 April 1993
Published online: 15 August 2000

Keywords

Authors

Affiliations

Manjula K. Pandit, MD
From the Louisville Veterans Affairs Medical Center and the University of Louisville, Louisville, Kentucky; the Fargo Veterans Affairs Medical Center and the University of North Dakota, Fargo, North Dakota.
John Burke, RPh, MA
From the Louisville Veterans Affairs Medical Center and the University of Louisville, Louisville, Kentucky; the Fargo Veterans Affairs Medical Center and the University of North Dakota, Fargo, North Dakota.
Anthony B. Gustafson, MD
From the Louisville Veterans Affairs Medical Center and the University of Louisville, Louisville, Kentucky; the Fargo Veterans Affairs Medical Center and the University of North Dakota, Fargo, North Dakota.
Anil Minocha, MD
From the Louisville Veterans Affairs Medical Center and the University of Louisville, Louisville, Kentucky; the Fargo Veterans Affairs Medical Center and the University of North Dakota, Fargo, North Dakota.
Alan N. Peiris, MD
From the Louisville Veterans Affairs Medical Center and the University of Louisville, Louisville, Kentucky; the Fargo Veterans Affairs Medical Center and the University of North Dakota, Fargo, North Dakota.
Corresponding Author: Alan N. Peiris, MD, VAMC-151A, 800 Zorn Avenue, Louisville, Kentucky 40206.
Acknowledgments: The authors thank Nancy Fletcher for secretarial assistance, Paul Matuschka and the Pharmacy staff, and Lynn Thomason and the Medical library staff at the Louisville Veterans hospital for invaluable help during the preparation of this article, and Vasti Broadstone, MD, for comments.

Metrics & Citations

Metrics

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Manjula K. Pandit, John Burke, Anthony B. Gustafson, et al. Drug-Induced Disorders of Glucose Tolerance. Ann Intern Med.1993;118:529-539. doi:10.7326/0003-4819-118-7-199304010-00008

View More

Get Access

Login Options:
Purchase

You will be redirected to acponline.org to sign-in to Annals to complete your purchase.

Create your Free Account

You will be redirected to acponline.org to create an account that will provide access to Annals.

View options

PDF/ePub

View PDF/ePub

Related in ACP Journals

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media